<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525107</url>
  </required_header>
  <id_info>
    <org_study_id>ORG/HSS/14/013</org_study_id>
    <nct_id>NCT02525107</nct_id>
  </id_info>
  <brief_title>Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements</brief_title>
  <acronym>OM3FA</acronym>
  <official_title>Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sultan Qaboos University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Sultanate of Oman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Metropolitian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sultan Qaboos University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD
      patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan
      Qaboos University Hospital [SQUH] haematology specialty clinics. Patients will be randomized
      in a 1:1 ratio to receive placebo or Omega-3 for 52 weeks. The aim is to investigate the
      therapeutic potential of omega-3 fatty acids in the prevention of vaso-occlusive crisis in
      Omani patients with sickle cell disease[SCD].
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of VOC</measure>
    <time_frame>52 weeks</time_frame>
    <description>Reduction of the number of Emergency and Hospital visits for VOC episodes compared to the previous 52 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of VOC</measure>
    <time_frame>52 weeks</time_frame>
    <description>Reduction in the average visual analog score for pain with scores ranging from 0[no pain] to 10[worst possible pain] recorded during VOC episodes compared to the previous 52 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>52 weeks</time_frame>
    <description>Reduction in the number of days in hospital with VOC pain compared to the previous 52 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red blood cells membrane fatty acids profile</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measurement of red blood cell membrane ethanolamine phosphoglyceride[DHA, EPA, AA] at baseline and after 52 weeks intervention period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>SCD patients on Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD patients not on Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 capsules</intervention_name>
    <description>SCD patients on Hydroxyurea</description>
    <arm_group_label>SCD patients on Hydroxyurea</arm_group_label>
    <other_name>Omega-3 Fatty acid, fish oil supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SCD patients on Hydroxyurea</description>
    <arm_group_label>SCD patients on Hydroxyurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 capsules</intervention_name>
    <description>SCD patients not on Hydroxyurea</description>
    <arm_group_label>SCD patients not on Hydroxyurea</arm_group_label>
    <other_name>Omega-3 Fatty acid, fish oil supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SCD patients not on Hydroxyurea</description>
    <arm_group_label>SCD patients not on Hydroxyurea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe Sickle cell disease patients.

          -  Patients already receiving Hydroxyurea[HU] are eligible for the study.

          -  Patients able and willing to comply with the procedures in the study protocol.

        Exclusion Criteria:

          -  Acute episodes (infection, vaso-occlusive crises (VOC), acute chest syndrome (ACS),
             stroke, priapism, splenic sequestration) in the past one month before enrolment.

          -  Previous stroke, and other co-morbid diseases like Essential Hypertension,
             Cardiomyopathy and Heart failure, Diabetes, Chronic Renal Failure.

          -  Patients with a history of adverse reaction to omega-3 fatty acid supplementation.

          -  Blood transfusion in the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Salam Alkindi, MD, FRCPI</last_name>
    <phone>+968-99353188</phone>
    <email>sskindi@squ.edu.om;sskindi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anil Pathare, MD,PhD</last_name>
    <phone>+968-99384951</phone>
    <email>pathare@squ.edu.om;avp16@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Haematology, Sultan Qaboos University</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salam Alkindi, MD</last_name>
      <phone>+96824144947</phone>
      <phone_ext>4947</phone_ext>
      <email>sskindi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Oman</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sultan Qaboos University</investigator_affiliation>
    <investigator_full_name>Salam Alkindi</investigator_full_name>
    <investigator_title>Professor &amp; Head, Department of Haematology</investigator_title>
  </responsible_party>
  <keyword>Prevention of Vaso Occlusive Painful Crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

